Skip to content
Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
Menu
  • Pα+
Search
Join Pα+
  • Sign in
Menu
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Read more about the article Psychedelic Research Bulletin: February 2023

Psychedelic Research Bulletin: February 2023

  • Post published:March 24, 2023
  • Post category:Psychedelics Research Review
Read more about the article atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

  • Post published:March 24, 2023
  • Post category:Press Release
Read more about the article Psyence Group Announces Cantheon Capital Private Placement

Psyence Group Announces Cantheon Capital Private Placement

  • Post published:March 23, 2023
  • Post category:Press Release
Read more about the article Field Trip Health & Wellness Obtains CCAA Protection

Field Trip Health & Wellness Obtains CCAA Protection

  • Post published:March 22, 2023
  • Post category:Press Release
Read more about the article Promise of BetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress Article

Promise of BetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress Article

  • Post published:March 22, 2023
  • Post category:Press Release
Read more about the article Numinus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023

Numinus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023

  • Post published:March 22, 2023
  • Post category:Press Release
Read more about the article Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023

Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023

  • Post published:March 21, 2023
  • Post category:Press Release
Read more about the article Wesana Health Announces Sale of SANA-13 Assets to Lucy Scientific Discovery

Wesana Health Announces Sale of SANA-13 Assets to Lucy Scientific Discovery

  • Post published:March 21, 2023
  • Post category:Press Release
Read more about the article Psyence Partners with iNGENÅ« for Palliative Care Clinical Trial in Australia

Psyence Partners with iNGENÅ« for Palliative Care Clinical Trial in Australia

  • Post published:March 21, 2023
  • Post category:Press Release
Read more about the article Algernon Pharmaceuticals Announces Launch of Rights Offering

Algernon Pharmaceuticals Announces Launch of Rights Offering

  • Post published:March 21, 2023
  • Post category:Press Release

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2026, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More